ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals (ANIP) stock research: performance, analysts' price targets, earnings, revenue and margins, technicals and insider trades.

ANIP Slips as Investors Weigh Egetis Deal

ANI Pharmaceuticals is down 1.8% today while the S&P 500 and Nasdaq 100 are higher. The company announced another investor conference, but attention may remain on its proposed Egetis acquisition and the financing and first-year earnings dilution tied to the deal.

Published 2026-11-19 15:01:13 UTC.